National Academies’ Report Reaffirms the Science of Climate Harm, Underscores Public-Health Risks
- HEALTH, LIFESTYLE, NEWS, SCIENCE-TECH, WORLD
- September 22, 2025

On a chilly Friday evening in the small Midwestern town of Mapleton, where high school football usually commands center stage, the roar inside the school gym wasn’t for a touchdown or a buzzer-beating shot. It was for a group of teenagers huddled around a robot, a compact machine of aluminum and wiring that had just
READ MORE
The National Academies of Sciences, Engineering, and Medicine this month published a comprehensive review concluding that evidence linking greenhouse-gas emissions to worsening U.S. climate impacts and attendant public-health and welfare harms is robust and “beyond scientific dispute,” a finding that has re-energized scientific and policy debates because it directly rebuts attempts to downplay or rescind
READ MORE
On the Samsung side, recently the company has been aggressively updating software features and refining its foldable hardware (Fold7, Flip7), alongside pushing forward its AI-enabled user experience through One UI 8 and deeper security enhancements. The rollout of One UI 8 begins with the Galaxy S25 series and will expand to other Galaxy devices (S24,
READ MORE
NASA announced launch coverage this month for three new space-weather missions slated to lift on a SpaceX Falcon 9, a focused campaign that reflects U.S. priorities in protecting critical infrastructure (power grids, satellites, communications) from solar storms and charged-particle events that can cascade into economic and safety risks on Earth; the missions part of a
READ MORE
Apple’s fall 2025 launch has delivered significant updates with its iPhone 17 line and the accompanying release of iOS 26, these changes not only refine what users expect of Apple’s flagship offerings but also shift strategic product positioning and market dynamics. Beginning with the iPhone 17 positioned as the entry-price flagship among the new models
READ MORE
n a development that could meaningfully alter patient experience and clinic workflows for a broad set of oncology patients, the U.S. Food and Drug Administration on September 19 approved a subcutaneous (under-the-skin) formulation of pembrolizumab branded Keytruda Qlex that reduces administration time from the typical half-hour intravenous infusion to a one-to-two-minute injection depending on dose;
READ MORE